KNSA
Kiniksa Pharmaceuticals, Ltd.
KNSA has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over KNSA overall, supported by stronger valuation.
KNSA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Healthy |
KNSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
KNSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.2x | $6.87 | -93% |
| Forward | 63x | $96.28 | — |
| Fair | 67x | $87.85 | -8.8% |
| Current | 74x | $96.28 | — |
| Expensive | 143x | $188 | +95% |
Historical ranges are pointers, not guarantees.
KNSA's PE is in its fair range at 74x. If earnings grow as analysts expect, today's price would be 63x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over KNSA in the historical PE scenario, which offers more potential upside but is not a forecast.
KNSA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for KNSA, but weaker profitability. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over KNSA on the outlook, with more favorable profitability expectations.
KNSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | +16% |
| Q3 2026 | $1.31 | +185% |
| Q2 2026 | $0.98 | +1860% |
| Q1 2026 | $0.91 | +$1.15 |
| Q4 2025 | $0.75 | +$1.35 |
| Q3 2025 | $0.46 | +$0.58 |
| Q2 2025 | $0.05 | +$0.19 |
| Q1 2025 | -$0.24 | -285% |
| Q4 2024 | -$0.60 | -400% |
KNSA has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
KNSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $286M | +58% |
| Q2 2026 | $243.6M | +55% |
| Q1 2026 | $214.3M | +56% |
| Q4 2025 | $202.1M | +65% |
| Q3 2025 | $180.9M | +61% |
| Q2 2025 | $156.8M | +44% |
| Q1 2025 | $137.8M | +73% |
| Q4 2024 | $122.5M | +47% |
KNSA has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +5.7 points |
| Q2 2026 | 11% | -1.7 points |
| Q1 2026 | 14% | +4 points |
| Q4 2025 | 9.8% | +26 points |
| Q3 2025 | 13% | +22 points |
| Q2 2025 | 13% | +13 points |
| Q1 2025 | 9.6% | +30 points |
| Q4 2024 | -16% | -16 points |
KNSA has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
KNSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.4M | +44% |
| Q2 2026 | $46.5M | +67% |
| Q1 2026 | $50M | +125% |
| Q4 2025 | $53.3M | +187% |
| Q3 2025 | $33M | +$35.2M |
| Q2 2025 | $27.9M | +440% |
| Q1 2025 | $22.2M | +469% |
| Q4 2024 | $18.6M | +335% |
KNSA has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
KNSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +1.5M shares |
| 1 year | +6.1% | +4.9M shares |
| 3 years | +21% | +14.7M shares |
| 5 years | +24% | +16.3M shares |
| Available history | +57% | +30.9M shares |
KNSA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
KNSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -4.4x | Net Cash |
| Q2 2025 | -32.1x | Net Cash |
| Q2 2023 | -2.8x | Net Cash |
| Q1 2023 | -3.3x | Net Cash |
KNSA has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over KNSA on leverage, with a lower net debt burden relative to earnings.
KNSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.8 | Overbought |
| Stochastic | 85.1 | Overbought |
KNSA's weekly RSI is 80 (overbought) and its Stochastic is 85 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
KNSA PE vs Healthcare Sector
| Metric | KNSA | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 184% above |
| PE % | 54 | 29 | 25 pts above |
KNSA is trading at 74x earnings, a 184% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over KNSA on valuation relative to its sector.
KNSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $83.5 | 15% above |
| 20 week MA | $76.9 | 25% above |
| 50 week MA | $59.0 | 63% above |
| 100 week MA | $43.7 | 121% above |
| 200 week MA | $30.9 | 211% above |
KNSA is in an uptrend: it's above all five of its weekly moving averages, and 211% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
KNSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.7 | $19.0 | +62% |
| 2021 | $19.0 | $13.1 | -31% |
| 2022 | $13.1 | $15.5 | +18% |
| 2023 | $15.5 | $17.5 | +13% |
| 2024 | $17.5 | $20.0 | +14% |
| 2025 | $20.0 | $42.0 | +110% |
| 2026 YTD | $42.0 | $96.3 | +129% |
KNSA has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.